Which TNT strategy to choose for which cancer
Monday, 30 November 2026, 2:15 pm
Rodrigo Perez
Rodrigo Pérez emphasizes that the future of total neoadjuvant therapy lies in tailoring treatment to tumor biology and individual risk, rather than applying a one-size-fits-all approach. The optimal sequence and intensity—from induction versus consolidation chemotherapy to the role of radiotherapy—should be selected according to disease characteristics, systemic risk, and the goal of organ preservation. The message: TNT is not a single strategy, but a toolbox to be matched to the right patient and tumor.
About Rodrigo Perez
Rodrigo Oliva Perez is a leading colorectal surgeon and researcher based in São Paulo, Brazil, with appointments at the University of São Paulo and Hospital Alemão Oswaldo Cruz. He has made seminal contributions to the development and validation of watch-and-wait strategies, particularly in defining clinical complete response, patient selection, surveillance and the management of local regrowth. His work has been instrumental in shaping the contemporary evidence base for non-operative rectal cancer management and has contributed to the evolution of multidisciplinary, organ-preserving care.
European Colorectal Congress 2026
See the full program and secure your seat.
You might also be interested in
-
Brachytherapy: what are the benefits?
Cristina Picardi argues that, for selected rectal-cancer patients, Papillon contact X-ray brachytherapy enables highly targeted intratumoral dose escalation – a key factor…
-
Can we convert CRC-MSS tumors to be responsive to immunotherapy?
Michael Bergmann argues that MSS colorectal cancers may be made responsive to immunotherapy by reprogramming their immunologically “cold” tumour microenvironment.
-
Near complete response: what to do now?
Geerard Beets contests the notion that a near-complete response should invariably result in TME, as further tumour regression remains a possibility.